𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features

✍ Scribed by Gulnur Guler; Cigdem Himmetoglu; Rafael E. Jimenez; Susan M. Geyer; Wenle P. Wang; Stefan Costinean; Robert T. Pilarski; Carl Morrison; Dinc Suren; Jianhua Liu; Jingchun Chen; Jyoti Kamal; Charles L. Shapiro; Kay Huebner


Publisher
Springer US
Year
2010
Tongue
English
Weight
802 KB
Volume
129
Category
Article
ISSN
0167-6806

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Distinct patterns of DNA copy number alt
✍ Anna Bergamaschi; Young H. Kim; Pei Wang; Therese SΓΈrlie; Tina Hernandez-Boussar πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 525 KB

## Abstract Breast cancer is a leading cause of cancer‐death among women, where the clinicopathological features of tumors are used to prognosticate and guide therapy. DNA copy number alterations (CNAs), which occur frequently in breast cancer and define key pathogenetic events, are also potentiall

Expression and splicing of the unfolded
✍ Michael P.A. Davies; Dong Liu Barraclough; Ceri Stewart; Kathryn A. Joyce; Richa πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 French βš– 92 KB

## Abstract X‐box binding protein 1 (XBP‐1) is stimulated by endoplasmic reticulum stress as part of the unfolded protein response (UPR), which can promote apoptosis or cell survival. Non‐conventional splicing, stimulated during the UPR, converts mRNA for β€œunspliced” XBP‐1U to β€œspliced” XBP‐1S mRNA

Expression of p27Kip1 and cyclin D1 prot
✍ Han, Sehwan; Kim, Hong-Yong; Park, Kyeongmee; Lee, Myung-Soo; Kim, Hong-Joo; Kim πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 318 KB πŸ‘ 2 views

Background and Objectives: p27Kip1 is an inhibitor of cyclindependent kinases and is speculated to be a potential prognostic indicator in numerous human cancers. We investigated expression of p27Kip1 along with cyclin D1 in gastric cancer to estimate the clinical utility of p27Kip1. Methods: Immunoh